An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2394 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Diane D Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pfizer Research and Development, Pfizer, San Diego, CA, USA. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The current regulatory path for new drug registration in East Asian countries has led to significant delay of the new medicines in these countries. A unified regulatory path and allowance of mutual usage of clinical data in East Asian countries would lead to cost saving in drug development and expedite the new drug registration in these countries. The objectives of the present analysis are to compare the approval dates of a selection of products developed by Pfizer in the United States and East Asian countries (China, Japan, Korea) and compare the pharmacokinetics and recommended doses of these products in East Asian countries. Eighteen products (20 drugs, 2 products with 2 combination drugs) with exposure data available in at least 2 of the 3 East Asian countries across different therapeutic areas were included in the analyses. The results showed that most products had delayed approval in East Asian countries (up to 8 years) after US or EU approval. No distinct differences were observed in the drug exposure and recommended doses for the selected products in East Asian countries. These results together with literature data of genetic similarity of the East Asian populations support the mutual usage of the clinical data in the East Asian countries for expedited regulatory submission and approval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology, Pfizer Research and Development, Pfizer, San Diego, CA, USA.
- Pfizer R&D Japan, Tokyo, Japan.
- Shinjuku Bunka Quint Bldg, Shibuya-ku, Tokyo, Japan.
- Pfizer Investment Co. Ltd., Development China, Dongcheng District, Beijing, China.
- Pfizer Pharmaceuticals Korea Ltd, Global Regulatory Sciences, Jung-gu, Seoul, Republic of Korea.
ORCID-Profile: Yanke Yu
Zitieren
APA
Wang, D. D., Yu, Y., Fukuhara, K., Liu, Y., Park, S. Y., & Parivar, K. (2024). An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2394
Vancouver
Wang DD, Yu Y, Fukuhara K, Liu Y, Park SY, Parivar K. An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2394
BibTeX
@article{Wang2024,
author = {Wang, Diane D and Yu, Yanke and Fukuhara, Kei and Liu, Yuwang and Park, So-Young and Parivar, Kourosh},
title = {An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2394}
}
EUVIMED